ECHA: Open invitations for notifications

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

ECHA: Public consultations on applications for authorisation

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Public Consultation: EU drugs strategy 2013-20 – evaluation

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Press Release: Have your say on the future of the Active and Assisted Living Programme

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Call for submissions: good practices of intersectoral collaboration to end HIV, tuberculosis and viral hepatitis

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Questionnaire: Mapping personalised medicine and health policies in European regions

SAPHIRe – Securing the adoption of personalised health in regions – is a three year project (2019-2021) funded by the European Commission (DG Research and Innovation) under the Horizon 2020 programme and is managed by a consortium consisting of the department of Economy, Science and Innovation of the Flemish Government, the Public Health Agency of Northern Ireland and EIT. The aim of the project is to map personalised medicine and health policies in European regions and to establish and support networking between interested regions in order to facilitate interregional collaboration and identify opportunities for funding of joint projects.

Public Stakeholder Consultation: Health PPP Strategic Research & Innovation Agenda

Five health industry associations are currently in discussions towards the creation of a Public-Private Partnership under Horizon Europe, the next EU Framework Programme for Research & Innovation. As part of the creation of the partnership, all relevant stakeholders and the public are invited to contribute to the development of the Strategic Research Agenda.

Have your say on the next generation of ambitious research and innovation partnerships

The Commission invites anyone with an interest in future research and innovation partnerships to participate in the survey, which will close on 6 November 2019.

Consultation: Call for data on ingredients with potential endocrine-disrupting properties used in cosmetic products

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. Cookies help you create your Policy Newsfeed for example. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close